. Author manuscript; available in PMC: 2012 Mar 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Mar 4;82(2):635–642. doi: 10.1016/j.ijrobp.2010.11.048

Table 2.

Incidence of recorded toxicities in patients with parameningeal rhabdomyosarcoma: Comparison of proton data with previously published studies

Toxicity	Protons: MGH (n = 10) Median f/u: 5 y		IRS II-III (n = 213) Median f/u: 7 y		IMRT: MSKCC^† (n = 21) Median f/u: 2 y		University of Iowa^‡ (n = 17) Median f/u: 20 y
Toxicity	n	%	n	%	n	%	n	%
Decreased growth velocity	3/10	30	92/190	48	NR		9/15	60
Growth hormone replacement	2/10	20	36/190	19	1/21	5	6/15	40
Other endocrinopathies	1/10	10	17/213	8	NR		1/15	7
Facial hypoplasia	7/10	70	74/76	97	1/21	5	11/15	73
Visual complications	0		45/213	21	2/21	10	9/11	82
Auditory complications	0		36/213	17	NR		6/8	75
Dentition	3/10	30	NR		NR		7/7	100
Chronic nasal and sinus congestion	2/10	20	35/71	49	4/21	19	NR
Secondary malignancies	0		4/213	2	2/21	10	1/17	6

Abbreviations: MGH = Massachusetts General Hospital; f/u = follow-up; IRS = Intergroup Rhabdomyosarcoma Study Group; IMRT = intensity-modulated radiotherapy; MSKCC = Memorial Sloan-Kettering Cancer Center; NR = not reported.

Reference (10).

^†

Reference (16).

^‡

Reference (17).